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ABSTRACT Cancer-derived loss-of-function mutations in the KEAP1 tumor suppres-
sor gene stabilize the NRF2 transcription factor, resulting in a prosurvival gene ex-
pression program that alters cellular metabolism and neutralizes oxidative stress. In
a recent genotype-phenotype study, we classified 40% of KEAP1 mutations as ANCHOR
mutants. By immunoprecipitation, these mutants bind more NRF2 than wild-type
KEAP1 and ubiquitylate NRF2, but they are incapable of promoting NRF2 degrada-
tion. BioID-based protein interaction studies confirmed increased abundance of NRF2
within the KEAP1 ANCHOR mutant complexes, with no other statistically significant
changes to the complexes. Discrete molecular dynamic simulation modeling and
limited proteolysis suggest that the ANCHOR mutations stabilize residues in KEAP1
that contact NRF2. The modeling supports an intramolecular salt bridge between
the R470C ANCHOR mutation and E493; mutation of the E493 residue confirmed the
model, resulting in the ANCHOR phenotype. In live cells, the KEAP1 R320Q and
R470C ANCHOR mutants colocalize with NRF2, p62/SQSTM1, and polyubiquitin in
structured spherical droplets that rapidly fuse and dissolve. Transmission electron
microscopy coupled with confocal fluorescent imaging revealed membraneless
phase-separated biomolecular condensates. We present a model wherein ANCHOR mu-
tations form p62-dependent biomolecular condensates that may represent a transi-
tional state between impaired proteasomal degradation and autophagy.
KEYWORDS KEAP1, NRF2, mutations, lung cancer, hypomorphs, clusters,
biomolecular condensates, liquid-liquid phase separation, membraneless organelles,
autophagy, oxidative stress, p62/SQSTM1
The National Cancer Institute projects more than 234,000 new cases of lung cancer,with mortalities in excess of 154,050 people, for 2018 (1). Lung squamous cell
carcinomas (LUSC) comprise 25 to 30% of all lung cancer cases, with a 5-year survival
rate of less than 5% for patients with stage IV disease, thus demonstrating a clear need
for earlier diagnostic measures and novel therapeutic treatments (2–4). Comprehensive
studies conducted by The Cancer Genome Atlas (TCGA) revealed mutations in the
Kelch-like ECH-associated protein 1 (KEAP1) and nuclear factor erythroid 2-related
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factor 2 (NFE2L2; here referred to as NRF2) pathway in 34% of LUSC cases studied,
underscoring the significance of this pathway in lung tumorigenesis (5).
KEAP1 functions as an intracellular sensor of oxidative stress (5–7). Under basal
conditions, cytosolic KEAP1 exists as a homodimer and associates with the E3 ubiquitin
ligase complex cullin-3 (CUL3) and RBX1 via a three-box motif in its broad-complex,
tramtrack, bric-à-brac (BTB) domain (6–10). Dimeric KEAP1 binds two different motifs
within NRF2: a high-affinity ETGE and a low-affinity DLG. These motifs bind an arginine
triad motif in the KELCH domains of KEAP1 (11–14). The prevailing model is that the
association of both motifs with a KEAP1 homodimer sterically positions lysine residues
in NRF2 for ubiquitylation (7–11, 13). Ubiquitylated NRF2 is then delivered to the
proteasome for degradation, though the precise mechanisms of this transition are
unresolved. Electrophilic modifications to one or more of the 27 reactive cysteine
residues in KEAP1 result in a conformational change that impairs NRF2 degradation
(15–19). Consequently, in the absence of free homodimeric KEAP1, de novo-synthesized
NRF2 accumulates and translocates to the nucleus (11, 20, 21). Nuclear NRF2 het-
erodimerizes with small Maf proteins and binds to antioxidant response elements
(ARE)/electrophile response elements (EpRE) in the promoters of target genes, includ-
ing the phase II detoxifying enzyme NAD(P)H dehydrogenase [quinone] 1 gene (NQO1),
glutathione synthesis genes, and heme oxygenase 1 gene (HMOX1) (20–22).
Live-cell imaging studies utilizing fluorescence lifetime imaging (FLIM) coupled with
Förster resonance transfer (FRET) constructs established that KEAP1 cycles between two
distinct conformations: open and closed (15). Initially, KEAP1 exists in the cytosol as a
homodimer with a 1:1 stoichiometry with the CUL3 complex (15, 23, 24). As NRF2
protein levels increase, KEAP1 binds the ETGE motif of NRF2, thus establishing the open
conformation of the KEAP1-NRF2 complex (15). Binding of the low-affinity DLG motif
generates the closed conformation of the complex, in which ubiquitylation of NRF2 is
sterically favorable (15). The closed complex delivers ubiquitylated NRF2 to the pro-
teasome for degradation, and removal of the ubiquitylated substrate results in regen-
eration of free and open KEAP1, enabling cycling to continue (15). Reactive oxygen
species and electrophilic compounds modify KEAP1 conformation, resulting in im-
paired cycling and accumulation of the closed KEAP1-NRF2 complex (15). In order to
reestablish redox-sensing capabilities, cells must regenerate free KEAP1 and remove
KEAP1-NRF2 closed complexes; the mechanism of how this occurs has yet to be fully
elucidated (15, 25–27).
Due to its essential role in mitigating oxidative stress, a delicate balance of KEAP1-
NRF2 signaling is required to maintain cellular homeostasis. Inappropriately low or high
NRF2 activity is associated with a variety of disease conditions (5, 16, 28, 29). Diminished
or absent NRF2 activity is associated with an increased risk for neurodegeneration and
aging (16, 30, 31). In contrast, prolonged periods of NRF2 hyperactivation correlate with
an increased risk for tumorigenesis (31–34). In greater than 30% of lung cancers,
mutations in KEAP1 or NRF2 contribute to constitutive NRF2 activity, which correlates
with increased resistance to chemotherapy and poor patient outcome (5, 10, 31, 32,
35–37).
Although over 700 somatic mutations in KEAP1 have been identified in cancer, the
mechanism and functional consequences of the majority of these mutations remain
unknown (38, 39). Analysis of 178 LUSC patients directed by the TCGA Consortium
revealed 18 mutations in KEAP1 (5). To determine the functional significance of these
mutations in LUSC, we cloned and profiled the mutants to define their impact on NRF2
function and biochemical activity (40). From these data, we identified three distinct
functional classes: (i) silent mutations which most likely represent passenger events, (ii)
hypomorphic mutations, and (iii) functionally dead proteins (40). Further interrogation
of the hypomorphic mutant class revealed seven mutations which exhibit increased
binding to NRF2 by immunoprecipitation yet lack the ability to suppress NRF2 tran-
scription (40). Here we refer to this class of KEAP1 mutations as ANCHOR mutants
(additionally NRF2-complexed hypomorph). These ANCHOR mutations were previously
referred to as superbinders; however, because binding affinities remain to be defined,
Cloer et al. Molecular and Cellular Biology
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the term superbinder was replaced with ANCHOR for clarity. Remarkably, cell-based
and in vitro studies determined that the KEAP1 R320Q ANCHOR mutation retains the
ability to ubiquitylate NRF2 (40).
From our analyses of the LUSC KEAP1 mutations, we estimate that KEAP1 ANCHOR
mutations represent more than one-third of patient-derived LUSC KEAP1 mutations. In
this study, we examined the mechanism and phenotypic consequences of the ANCHOR
mutants. Proximity-based proteomic analyses of KEAP1 ANCHOR complexes revealed
exclusive enrichment of NRF2, with minimal impact on other KEAP1-associated pro-
teins. Structural molecular dynamic simulations and biochemical studies suggest that
ANCHOR mutants stabilize KEAP1 tertiary structure, particularly at interfacing residues
with NRF2. In cells, ANCHOR mutants form spherical clusters containing polyubiquitin,
the autophagy cargo adaptor p62/SQSTM1 (p62), KEAP1, and NRF2. The formation of
these clusters is p62 dependent, yet surprisingly, the clusters are not cleared by
autophagy. Live-cell imaging and transmission electron microscopy (TEM) establish the
clusters as membraneless organelles with liquid-like properties, defining features of
biomolecular condensates. As expected, overexpression of KEAP1 ANCHOR mutants
protects cells from DNA damage. Together, these studies provide new insight into the
function of KEAP1 ANCHOR mutations.
RESULTS
The mutational landscape of NRF2 and KEAP1. Across many cancer types,
inactivating mutations in KEAP1 and activating mutations in NRF2 are mutually exclu-
sive. Further, KEAP1 mutations lack positional enrichment, whereas mutations in NRF2
localize to the KEAP1 binding sites, features that are consistent with tumor suppressor
and oncogene functions, respectively (5, 38, 40–48). To illustrate these patterns, we
compiled mutation data from cBioPortal into kernel density estimation (KDE) plots (Fig.
1A and B; see also Tables S1 and S2 in the supplemental material) (38, 39). In NRF2, 448
mutations localize almost exclusively to the DLG and ETGE motifs, which are required
for binding to KEAP1 (Fig. 1A) (40). In contrast, the 718 mutations identified in KEAP1
lack appreciable focal enrichment (Fig. 1B) (5, 38, 40, 43). Known ANCHOR mutations
also do not colocalize within KEAP1. Two of the three most frequently mutated residues
in KEAP1 are R320 and R470, and mutations to both of these residues result in an
ANCHOR phenotype (Fig. 1B) (40).
We hypothesized that functionally relevant mutations in NRF2 and KEAP1 would
occur more frequently at evolutionarily conserved amino acid residues compared to
passenger mutations or nonmutated residues. To test this, we examined the correlation
between mutational frequency (MF) and evolutionary conservation as estimated by
Shannon entropy (SE) for a given amino acid residue (Fig. 1C to F) (38, 49, 50).
MF-versus-SE plots for NRF2 and KEAP1 revealed a general trend of cancer-derived
mutations affecting evolutionarily conserved residues (Fig. 1C and D). For both NRF2
and KEAP1, the difference between SE for nonmutated and mutated residues was
statistically significant (Fig. 1E and F). Therefore, these data contribute to previous
studies which demonstrated evolutionary conservation of oncogenic mutations in
tumor suppressors and oncogenes, including TP53 (51, 52). Although multiple amino
acid substitutions are observed at the ANCHOR residues R320 and R470, we chose to
further characterize the R320Q and R470C mutations identified in the TCGA LUSC data
set (5).
Biochemical characterization of the KEAP1 ANCHOR mutants. To explore the
mechanism of the ANCHOR mutants, we examined NRF2 stability and KEAP1-NRF2
association. We first probed the dynamics of NRF2 stabilization using live-cell imaging.
HEK 293T/17 cells transiently overexpressing murine EGFP-Nrf2 (mEGFP-Nrf2) or human
Venus-NRF2 (Venus-NRF2) were monitored every hour for 24 h, and NRF2 stabilization
was plotted as a function of green fluorescence intensity. Analysis of fluorescent NRF2
intensity confirmed that KEAP1 R320Q and R470C rapidly stabilized NRF2 within hours
of transfection (Fig. 2A); similar stabilization was observed in H1299 lung adenocarci-
noma cells (data not shown). NRF2 stabilization in the presence of KEAP1 R320Q
Phase Separation of Mutant KEAP1 Molecular and Cellular Biology
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FIG 1 Defining the mutational landscape of NRF2 and KEAP1. (A) Kernel density estimation (KDE) of 448 NRF2 somatic mutations
demonstrates focal enrichment of mutations at the DLG and ETGE motifs, which are required for KEAP1 association. Fourteen patients
exhibited in-frame deletions across the DLG and/or ETGE; five patients had NFE2L2 intragenic fusion events, and one patient had a
ZNF385B-NFE2L2 fusion. Data from these patients were not included in the KDE analysis; only missense mutations were used to
compute the KDE. Data were downloaded from cBioPortal and represent NFE2L2mutations across 59 studies investigating 37 different
cancer types (Table S1) (38, 39). (B) KDE of 718 KEAP1 somatic mutations identified in patient samples reveals elevated mutational
frequencies at ANCHOR residues R320 and R470. Data were downloaded from cBioPortal and represent KEAP1 mutations across 68
studies investigating 33 different cancer types (Table S2) (38, 39). (C) Plot of NRF2 mutational frequency versus Shannon entropy.
Shannon entropy was calculated from the PROMALS3D sequence alignment, and mutational frequencies per residue were determined
from cBioPortal data (Table S3). (D) Comparison of Shannon entropy values for all nonmutated residues in NRF2 (n  459) versus
mutated residues (n  146). Error bars represent the standard error of the mean (SEM). The difference is statistically significant at
(Continued on next page)
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overexpression was also observed in HEK 293T/17 cells using immunofluorescence (IF)
(Fig. S1A).
Next, we compared KEAP1-NRF2 association using two complementary approaches:
immunopurification followed by Western blotting (IP/W.blot) and proximity ligation
assay (PLA). Analysis of IP/W.blot for FLAG-KEAP1 complexes from HEK 293T/17 cells
demonstrated that with the exception of G423V and G186R, the ANCHOR mutants were
expressed comparably to the wild type (WT). Furthermore, all ANCHOR mutants stabi-
lized endogenous NRF2 in the total cell lysate (Fig. 2B, lanes 3 to 9), although not to the
same extent as WT KEAP1 treated with the proteasome inhibitor MG-132 (Fig. 2B, lanes
10, 20, and 30). Analysis of the immunopurified complex demonstrated increased
association of NRF2 with all seven ANCHOR mutants (Fig. 2B, lanes 13 to 19) and
increased NRF2 protein levels in the unbound fraction (Fig. 2B, lanes 23 to 29). Not all
ANCHOR mutants are functionally equivalent; examination of the bound NRF2 suggests
that there are two distinct classes of ANCHOR mutants (Fig. 2B). In the first class, the
R320Q, R470C, D422N, and G186R mutants consistently bound more NRF2 than the
second ANCHOR class, consisting of the G423V, S243C, and V155F mutants (Fig. 2B,
compare lanes 13, 14, 16, and 17 with lanes 15, 18, and 19).
To determine localization and to further quantify KEAP1-NRF2 complex formation,
PLA (53, 54) was employed. Consistent with reported literature, confocal imaging
analysis of the PLA puncta demonstrated KEAP1-NRF2 complex formation primarily
within the cytosol (Fig. 2C) (15, 18, 23–25, 53, 54). Quantification of the PLA signal
confirmed a 2-fold increase in R320Q KEAP1-NRF2 complex formation compared to
that with the WT (Fig. 2D). To confirm the increased association of NRF2 with KEAP1
ANCHOR mutants in a more clinically relevant cell line, we performed PLA with H1299
lung adenocarcinoma cells. PLA of KEAP1 R320Q and R470C with endogenous NRF2
demonstrated increased KEAP1-NRF2 complex formation within the cytosol of the cell
compared to that with the WT (Fig. 2E). Additionally, we compared the stabilization of
the KEAP1-NRF2 complex in the presence of the ANCHOR mutants with a panel of NRF2
inducers: sulforaphane (SFN), bardoxolone-methyl (CDDO), MLN4924, and MG-132 (55,
56). The neddylation inhibitor MLN4924 was the most robust inducer of the NRF2-
KEAP1 PLA signal (Fig. 2E and F) (55, 56). Cysteine-modifying compounds SFN and
CDDO also stabilized the KEAP1-NRF2 complex but to a lesser extent than MLN4924 (19,
57–59). Moreover, the R320Q and R470C mutants stabilized the KEAP1-NRF2 interaction
comparably to treatment with the proteasomal inhibitor MG-132 (Fig. 2F; see also Fig.
S1D) (60). IF and WB were used to confirm equivalent expression of the FLAG-KEAP1
constructs as well as to assess NRF2 stabilization in H1299 cells (Fig. S1B to D).
Defining protein-protein interactions of KEAP1 ANCHOR mutants. Substrates
targeted for ubiquitylation are often low-abundance proteins or have transient inter-
actions that are difficult to detect by traditional immunopurification mass spectrometry
(IP/MS); therefore, we employed an unbiased MS approach to probe for additional
KEAP1 substrates and/or interacting proteins with altered association with the ANCHOR
mutants. BioID is a technique employing the use of a modified promiscuous biotin
ligase (BirA*) fused to a bait protein (61–63). Proteins that associate proximally with the
bait are biotinylated by the ligase and can be affinity purified using streptavidin and
detected by MS or W.blot analyses (61–63). Biotinylated complexes from HEK 293T/17
cells stably overexpressing BirA*-KEAP1 WT, R320Q, or R470C were affinity purified
using streptavidin, and eluted peptides were analyzed using liquid chromatography-
mass spectrometry (LC-MS/MS). Proteomic analyses revealed NRF2 as the only protein
significantly increased within KEAP1 R320Q protein complexes (Fig. 3A). NRF2 was also
significantly increased within KEAP1 R470C protein complexes (Fig. S2A).
FIG 1 Legend (Continued)
P  0.0033 using an unpaired t test. (E) Plot of KEAP1 mutational frequency versus Shannon entropy. Data were analyzed as for panel
C (Table S4). (F) Comparison of Shannon entropy values for all nonmutated residues (n  306) in KEAP1 versus mutated residues
(n  318). Error bars represent SEMs. The difference is statistically significant at a P value of 0.0004 using an unpaired t test.
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FIG 2 KEAP1 ANCHOR mutants stabilize NRF2 and increase KEAP1-NRF2 association. (A) HEK 293T/17 cells were cotransfected with FLAG-KEAP1 WT, R320Q,
or R470C and either EGFP-Nrf2 or Venus-NRF2 and immediately subjected to image acquisition using the IncuCyte Zoom. GFP and phase images were acquired
every hour at 20 with four fields/well. Data were plotted every 3 h, and total green object integrated intensity values were normalized by percentage
confluence. Each graph represents the average from three biological replicates, with four technical replicates per condition for each experiment. Error bars
represent standard errors from triplicates. (B) IP/W.blot of HEK 293T/17 cells transfected with indicated FLAG-KEAP1 constructs. At 18 h posttransfection, cells
were treated with DMSO or 10 M MG-132 for 6 h prior to harvest. Data are representative of those from a single experiment performed in biological triplicate.
(C) HEK 293T/17 cells stably expressing FLAG-KEAP1 WT or R320Q were subjected to PLA using FLAG and NRF2 antibodies for detection of overexpressed KEAP1
and endogenous NRF2 interactions (yellow). Images represent maximum intensity projections of Z-stacks acquired using a confocal microscope. For clarity, both
color and black-and-white images of the PLA dots are provided. Nuclei were stained with DAPI (blue), and microtubules were counterstained with antitubulin
antibody (green). Scale bar  20 m. (D) Fold induction relative to WT of KEAP1-NRF2 interaction in cells expressing R320Q. PLA dots were quantified and
normalized by cell number prior to calculation of fold induction. Data are presented as means SDs. *, P 0.001. Data are representative of those from a single
experiment performed in biological triplicate. (E) H1299 cells were transfected with FLAG-KEAP1 WT, R320Q, or R470C. The following day, cells were treated
with either DMSO (control) or a panel of NRF2 inducers—10 M MG-132, 5 M MLN4924, 375 nM CDDO, 50 M tBHQ, or 20 M SFN—for 6 h. Cells were then
(Continued on next page)
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To evaluate known KEAP1 substrates, IP/W.blot for all putative substrates was
performed. IP/W.blot from HEK 293T/17 cells overexpressing FLAG-KEAP1 WT or all
seven ANCHOR mutants confirmed that only NRF2 association increased with KEAP1
ANCHOR overexpression (Fig. 3B). Of the substrates examined, significant stabilization
of PALB2, MCM3, NRF1, IKBKB, or BCL2 in the input or in the bound complex was not
observed (Fig. 3B) (64–72). In contrast, PGAM5 stabilization was observed in the input
with KEAP1 ANCHOR mutants (Fig. 3B, compare lane 2 with lanes 3 to 9); however,
excluding G423V, PGAM5 association did not increase significantly with KEAP1 ANCHOR
overexpression (Fig. 3B, compare lane 11 with lanes 12 to 18). NRF1 and PGAM5
antibodies were confirmed using small interfering RNAs (siRNAs) (Fig. S2B and C).
Endogenous NRF1 protein levels were undetectable in the lysate but were detectable
following MG-132 treatment (Fig. 3B; see also Fig. S2B and C).
Probing mechanistic steps in KEAP1 cycling. Our data indicate that KEAP1
ANCHOR mutants stabilize NRF2 while maintaining NRF2 ubiquitylation, suggesting
that ANCHOR mutants may impair KEAP1 cycling or substrate release to the protea-
some (40). To test this hypothesis, different biochemical steps of the cycling process
were systematically evaluated. We first confirmed that KEAP1 ANCHOR mutants can
homodimerize by overexpressing N-terminally tagged streptavidin-binding peptide
and hemagglutinin-tagged KEAP1 (pIRESpuro-GLUE-KEAP1; here pGLUE-KEAP1) and
FIG 2 Legend (Continued)
fixed and subjected to PLA using FLAG and NRF2 antibodies for detection of KEAP1 interactions with endogenous NRF2 (yellow). Images represent a single
optical slice acquired using a confocal microscope as for panel C. Scale bar  20 m. (F) Fold induction relative to WT of KEAP1-NRF2 interaction in cells
expressing untreated WT, the R320Q or R470C mutant, or NRF2 inducer-treated WT. PLA dots were quantified and normalized by cell number prior to calculation
of fold induction. Data are presented as means  SDs. Data are representative of those from a single experiment performed in biological triplicate.
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FLAG-KEAP1 in Keap1/mouse embryonic fibroblasts (MEFs). These experiments were
conducted with a KEAP1 null cell line to eliminate potential contributions from endog-
enous KEAP1. First, IP/W.blot demonstrated that KEAP1 ANCHOR mutants retain the
ability to homodimerize (Fig. 4A). Second, KEAP1/CUL3 association was also examined
using transient overexpression of FLAG-KEAP1 ANCHOR mutants in Keap1/ MEFs.
IP/W.blot analyses confirmed that KEAP1 ANCHOR mutants associate with CUL3 com-
parably to KEAP1 WT (Fig. 4B). Third, given the previously reported interaction between
KEAP1 and the proteasomal chaperone HSP90, the interaction between KEAP1 WT or
R320Q and HSP90 was assessed (40, 73). Interactions between HSP90 and KEAP1 WT or
R320Q were not observed (Fig. S3A) (40, 73).
A recent report details the mechanism by which p97/valosin-containing protein
(VCP) and cofactors UFD1/NPL4 and UBXN7 remove ubiquitylated NRF2 from the
KEAP1-CUL3 complex for proteasomal delivery (27). These data were consistent with
our hypothesis that KEAP1 ANCHOR mutants impair proteasomal degradation down-
stream of ubiquitylation but prior to proteolysis; consequently, interaction between
KEAP1 and VCP was examined (27). In both HEK 293T/17 cells and Keap1/ MEFs, we
observed that KEAP1 WT, R320Q, and R470C bind VCP; however, no appreciable
difference in VCP association between KEAP1 WT and the two ANCHOR mutants was
detected (Fig. 4C and D). Treatment with VCP inhibitors CB-5083, DBeQ, and Eeyrestatin
1 (Eey1) modestly reduced VCP levels, with no effect on KEAP1 or NRF2 levels (Fig. 4E,
lanes 2 to 4 and 7 to 9) or association with KEAP1 WT or R320Q (Fig. 4E, lanes 12 to 14
and 17 to 19) (74–77). Finally, MG-132 treatment had no impact on VCP or KEAP1 levels
or association (Fig. 4E, lanes 5, 10, 15, and 20). VCP siRNAs were used to validate the VCP
antibody (Fig. S3B).
To test KEAP1 association with the proteasome, IP/W. blot for ubiquitin receptors
PSMD2 and PSMD4 was performed (78–85). IP/W.blot of FLAG-KEAP1 WT, R320Q, or
R470C demonstrated no differences in association with either PSMD2 or PSMD4
between KEAP1 WT or the ANCHOR mutants (Fig. 4F, lanes 7 to 9). Treatment with
MG-132 did not lead to increased association of KEAP1 WT with either PSMD2 or PSMD4
(Fig. 4F, lane 10). From these data, we conclude that aside from NRF2, ANCHOR
mutations do not impact KEAP1 protein-protein interactions.
Assessing KEAP1 ANCHOR structure. Modifications to cysteines within KEAP1 are
thought to alter KEAP1 architecture, thus impeding ubiquitin-dependent proteolysis of
substrates (19, 28, 59, 86). Mutations impacting cysteine reactivity or causing structural
deformation of KEAP1 could result in the ANCHOR phenotype. The lack of an available
full-length crystal structure for KEAP1 precluded molecular modeling to determine how
R320Q impacts KEAP1 structure; however, molecular modeling and simulations of the
KEAP1 KELCH domain could be used to investigate how the R470C ANCHOR mutation
may impact KEAP1 structure when complexed with NRF2.
Discrete molecular dynamics (DMD) simulation demonstrated that the R470C mu-
tation significantly reduced root mean square fluctuations (RMSF) of several residues
between amino acid numbers 500 and 550 (Fig. 5A) (87–90). A decrease in RMSF
corresponds to reduced motion, suggesting that the R470C mutation has a stabilizing
effect on these residues. When mapped to the crystal structure, decreases in RMSF were
observed to propagate throughout the KEAP1 KELCH domain and to contact loops with
the NRF2 degron (Fig. 5B).
To further confirm the effects of KEAP1 ANCHOR mutations on KEAP1 tertiary
structure, low-resolution limited trypsin proteolysis was performed (91). Lysates from
Keap1/ MEFs transiently overexpressing FLAG-KEAP1 WT, R320Q, or R470C were
exposed to increasing concentrations of trypsin. Although the molecular weight band-
ing patterns generated by trypsin were similar for the WT and the two ANCHOR
mutants, the intensity for bands between 50 and 70 kDa differed between KEAP1 WT
and the ANCHOR mutants. More specifically, the R320Q and R470C mutants were more
resistant to tryptic proteolysis than was KEAP1 WT (Fig. 5C, compare lanes 4 and 5 with
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lanes 11 and 12). These limited-proteolysis experiments suggest that R320Q and R470C
alter the structure of KEAP1, a finding that is consistent with the DMD simulations.
Examination of potential interactions with R470 revealed two acidic residues, D422
and E493, that are capable of forming a salt bridge with R470 (Fig. 5B). Interestingly,
mutation of D422 also results in an ANCHOR phenotype (Fig. 2B, lanes 6 and 16) (40);
therefore, we hypothesized that mutations to E493 may also result in an ANCHOR
phenotype. Analysis of cBioPortal data revealed a lung squamous cell carcinoma
patient (TCGA-18-5595-01) harboring a KEAP1 E493D mutation (38, 39). IP/W.blot of the
KEAP1 E493D mutation demonstrated stabilization of NRF2 in the whole-cell lysate
comparable to that with KEAP1 R320Q and R470C (Fig. 5D, compare lane 5 with lanes
3 and 4). Similarly, KEAP1 E493D bound NRF2 comparably to KEAP1 R320Q and R470C
(Fig. 5D, compare lane 11 with lanes 9 and 10). To determine the effect of the KEAP1
E493D mutation on NRF2 transcriptional activation, we used the hQR41-ARE luciferase
assay (92). The KEAP1 E493D mutant exhibited hypomorphic suppression of NRF2
transcriptional activity consistent with the ANCHOR class of mutations (Fig. 5E) (40).
KEAP1 stability and ubiquitylation were also assessed. Cycloheximide (CHX) chase
experiments under basal and oxidative stress-inducing tert-butylhydroquinone (tBHQ)
conditions confirmed that KEAP1 R320Q does not alter KEAP1 half-life (Fig. S4A and B)
(93, 94). IP/W.blot for ubiquitylated KEAP1 under native conditions demonstrated that
KEAP1 ANCHOR mutants did not alter KEAP1 ubiquitylation under basal or induced
(tBHQ and MG-132) conditions (Fig. S4C, lanes 15 and 16, 19 and 20, and 23 and 24),
nor did they alter KEAP1 K48 or K63 ubiquitin chain formation (Fig. S4D, lanes 11 to 16).
KEAP1 K48 ubiquitylation was further confirmed under near denaturing conditions
using an antibody for endogenous K48 ubiquitin (Fig. S4E, lanes 6 to 8).
KEAP1 ANCHOR mutants form p62-dependent biomolecular condensates. The
proposed impairment to KEAP1 structure led us to investigate KEAP1 localization in the
presence of the ANCHOR mutants. Fluorescently tagged constructs were used to
visualize the KEAP1-NRF2 complex in real time (15). We first tested subcellular local-
ization by independently overexpressing murine enhanced green fluorescent protein-
Nrf2 (mEGFP-Nrf2) or murine Keap1-mCherry (mKeap1-mCh) WT, R320Q, or R470C.
Consistent with recent reports, mEGFP-Nrf2 localized primarily to the nuclear compart-
ment in HEK 293T/17 and H1299 cells, with nuclear foci observed in H1299 (Fig. S5A
and B). In contrast, each of the mKeap1-mCh constructs resulted in a diffuse cytosolic
subcellular localization, with increased Keap1-positive clusters observed in H1299 cells
compared to HEK293T/17 cells (Fig. S5A and B) (15). Next, overexpression of mEGFP-
Nrf2 in the presence of mKeap1 WT, R320Q, or R470C was examined. A distinct increase
in Keap1-Nrf2-containing clusters was observed when mEGFP-Nrf2 was overexpressed
in the presence of the ANCHOR mutants in both HEK 293T/17 and H1299 cells (Fig. 6A;
see also Fig. S5C).
Cytoplasmic inclusions are characterized by insoluble protein aggregates; thus, the
Triton X-100 solubility assay was used to complement the fluorescence microscopy
data (95). Similar accumulations within the insoluble fractions for all of the FLAG-KEAP1
constructs were observed (Fig. 6B, lanes 12 to 14). However, NRF2 accumulation within
the insoluble fraction occurred only in the presence of R320Q and R470C or with KEAP1
WT treated with MG-132 (Fig. 6B, lanes 12 to 15).
Insoluble inclusion bodies and aggregate structures are often a hallmark of au-
tophagy, a bulk cellular recycling pathway involved in protein homeostasis (96–99).
KEAP1 binds the autophagy ubiquitin cargo adaptor p62/SQSTM1 (p62) via a KEAP1
FIG 5 Legend (Continued)
bound NRF2 peptide is colored magenta. The mutated residue R470 and the potential salt bridge partners are shown as sticks (red, acidic resides; blue, basic
residues). (C) W.blot of lysates from limited proteolysis of Keap1/ MEFs transiently transfected with FLAG-KEAP1 constructs and exposed to various
concentrations of trypsin for 15 min. (D) IP/W.blot of HEK 293T/17 cells transiently transfected with the indicated FLAG-KEAP1 constructs. Cells were treated
with 10 M MG-132 for 6 h. FLAG-KEAP1 complexes were immunopurified and probed for association with the indicated proteins. Data are representative of
those from a single experiment performed in biological triplicate. (E) hQR41-ARE luciferase assay of HEK 293T/17 cells transiently transfected with the indicated
FLAG-KEAP1 constructs. Data are presented as the average ratios of firefly (FF) to Renilla luciferase, with error bars representing SEMs across six technical
replicates. Data are representative of 5 biological replicates performed by two independent researchers.
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FIG 6 KEAP1 ANCHOR mutants interact with proteins involved in autophagy and form circular, insoluble clusters. (A) HEK 293T/17 cells were transiently
cotransfected with EGFP-Nrf2 (green) and Keap1-mChWT, R320Q, or R470C. DAPI stain was used to visualize nuclei (blue). Scale bar 20m; confocal images
are shown. (B) Triton X-100 solubility assay of HEK 293T/17 cells transiently transfected with the indicated FLAG-KEAP1 constructs. Sixteen hours posttrans-
fection, cells were treated with DMSO or 10 M MG-132 for 8 h. Data are representative of those from a single experiment performed in biological triplicate.
(C) IP/W.blot of HEK 293T/17 cells transfected with the indicated FLAG-KEAP1 constructs. FLAG-KEAP1 complexes were immunopurified and probed for the
indicated proteins. Data are representative of a single experiment performed in biological triplicate. (D) Time-lapse clearance of HEK 293T/17 cells cotransfected
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(G) Cluster diameter distribution in H1299 cells transiently expressing either Keap1-mCh WT (39 cells and 167 clusters analyzed) or R320Q (51 cells and 210
clusters analyzed). (H) Cluster circularity of Keap1-mCh R320Q-positive clusters (23 cells and 70 clusters analyzed).
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interaction region (KIR) in p62 and is itself degraded by autophagy (100–103). We
hypothesized that these clusters could represent autophagic flux of the KEAP1-NRF2
complexes with ANCHOR mutants. To evaluate KEAP1 association with components of
the autophagy pathway, we performed IP/W.blot. Analysis of immunopurified com-
plexes revealed that KEAP1 WT, R320Q, and R470C bound the autophagy cargo
adaptors next to BRCA-1 (NBR1), p62, and an autophagy-specific form of p62 phos-
phorylated at serine 351 (pS351) (104–106) (Fig. 6C) Furthermore, KEAP1 WT, R320Q,
and R470C bound VPS34, a class III phosphatidylinositol (PI) 3-kinase involved in the
initial formation of the autophagophore (98, 99, 107) (Fig. 6C).
Upon formation of the autophagophore, p62 and NBR1 bind to and transport
ubiquitylated substrates from the phagophore to the autophagosome, where the
substrates are tethered to a lipidated form of light chain 3 (LC3) (98, 108). Lipidated LC3
can be detected via W.blot as a faster-migrating band, and conversion of LC3 I and II
is routinely used as a marker of autophagic flux (96, 98, 108). KEAP1 WT, R320Q, and
R470C were all deficient for binding with LC3 (Fig. 6C, lanes 6 to 8).
Overexpression of KEAP1 WT, R320Q, and R470C did not alter the total protein levels
of NBR1 or VPS34; however, overexpression of KEAP1 WT, R320Q, and R470C resulted
in increased p62 and LC3 I and II conversion levels and decreased levels of p62 pS351
(Fig. 6C, compare lane 1 with lanes 2 to 4). There were no appreciable differences in the
effect of KEAP1 WT compared to the R320Q and R470C mutants with any of the
autophagy proteins (Fig. 6C, compare lane 2 with lanes 3 and 4).
In order to visualize the formation of these complexes, mEGFP-Nrf2 and mKeap1-
mCh R320Q were overexpressed in HEK 293T/17 cells for live-cell imaging studies.
These movies revealed that the smaller punctate structures combined to form larger
clusters that are ultimately cleared by the cell within a few hours (Fig. 6D; see also
Movies S1 and S2). Moreover, accumulation of these aggregates was not cytotoxic, as
several instances of cells proceeding through another round of division following
aggregate clearance were observed (Movies S1 and S2). Notably, the clusters in the
presence of R320Q were consistently larger (Fig. 6E to G). This difference in size was not
due to differences in KEAP1 expression (Fig. 6F). Furthermore, a majority of the
KEAP1-R320Q clusters exhibited a high degree of circularity, consistent with liquid-like
properties characteristic of phase separation (Fig. 6H) (109, 110). To further confirm the
morphology and subcellular architecture of the clusters, TEM coupled with correlative
confocal imaging analysis was performed. TEM revealed KEAP1-R320Q clusters lacking
a membrane, a defining characteristic of biomolecular condensates and membraneless
organelles (Fig. 7A) (109, 110). Further TEM imaging analysis identified cocompartmen-
talization of KEAP1-R320Q and NRF2 biomolecular condensates with autophagic vesi-
cles (AV) (Fig. 7B).
To identify the proteins contained in the biomolecular condensates, IF analysis of
mKeap1-mCh and mEGFP-Nrf2 in H1299 cells was performed, and results confirmed
that Keap1 and Nrf2 colocalize in the clusters (Fig. 8A). Moreover, IF analyses of
FLAG-NRF2 and mKeap1-mCh R320Q revealed spherical clusters coated with endoge-
nous polyubiquitin (polyUb), p62, and p62 pS351 (Fig. 8B). These clusters colocalized
with overexpressed EGFP-LC3 but not with the following proteins: (i) proteasomal
subunits (S20, PSMD2, or PSMD4) (Fig. S6), (ii) endogenous LC3, (iii) lysosomal marker
LAMP2, or (iv) LysoTracker under basal conditions or following treatment with the
autophagy inhibitor chloroquine (CQ) (Fig. S7A to C) (96, 97, 111). Furthermore, ATG5
siRNA depletion did not impact cluster formation or accumulation, suggesting that
autophagy upstream of ATG5 is not involved (Fig. S7D and E). Knockdown of p62 via
siRNA resulted in the absence of Keap1-NRF2 clusters (Fig. 8C; see also Fig. S7F). Taken
together, these data support the p62-dependent formation of spherical membraneless
organelles containing a KEAP1-positive core coated to various degrees with p62, p62
pS351, NRF2, and polyUb (Fig. 8D).
KEAP1 ANCHORmutants protect against chemotherapies that induce oxidative
stress. Prolonged NRF2 activation correlates with an increased resistance to chemo-
therapy and radiation treatment (22, 31–33, 36, 112–114). To determine the impact of
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ANCHORs on cell viability, H1299 cells stably overexpressing mKeap1-mCh WT, R320Q,
R470C, or mEGFP-Nrf2 were treated with bleomycin, which induces DNA damage via
oxidative stress (115); cell viability and apoptosis were assayed by PrestoBlue and
Caspase-Glo 3/7 assays, respectively (Fig. 9A; see also Fig. S8A). Analysis of 50%
effective concentrations (EC50 values) for bleomycin demonstrated that KEAP1 R470C
and R320Q exhibit significantly increased cell viability compared to KEAP1 WT (Fig. 9A)
(P  0.0001, unpaired t test). KEAP1 R320Q demonstrated a similar effect, though the
increased EC50 value for the R320Q mutant compared to the WT was not statistically
significant (Fig. 9A). To complement the cell viability data, levels of apoptotic induction
were quantified using Caspase-Glo 3/7. The R470C mutant exhibited decreased activa-
tion of executioner caspases, which was significantly different from the case for the WT
(Fig. 9B) (P  0.0002, unpaired t test). KEAP1 R320Q also exhibited lower levels of
activated caspases (Fig. 9B). Intriguingly, the protection conferred by the ANCHOR
mutants was specific to bleomycin, as similar effects were not observed with either
the DNA-damaging agent cisplatin or the microtubule destabilizer paclitaxel (Fig.
S8B and C).
DISCUSSION
Through biochemical and cell biology experimentation, we have defined five main
attributes of the KEAP1 ANCHOR class. First, KEAP1 ANCHOR mutants occur at well-
conserved and frequently mutated residues within KEAP1. Second, the KEAP1 ANCHOR
phenotype is exclusive to NRF2; the abundance of other KEAP1-interacting proteins is
unaffected. Third, KEAP1 ANCHOR mutants have a stabilizing effect on KEAP1 structure
that decreases flexibility at key residues interfacing with NRF2; furthermore, mutation
of the E493 residue identified from DMD simulation studies produces an ANCHOR
phenotype. Fourth, the ANCHOR mutants form p62-dependent biomolecular conden-
sates that are spherical and contain p62, p62 pS351, polyUb, and NRF2; these clusters
are not delivered to the autophagy pathway for clearance and are formed by phase
separation. Fifth, in the cell models tested, KEAP1 ANCHOR mutants show increased
resistance to bleomycin treatment but not to cisplatin or paclitaxel.
Looking across all mutations reported in KEAP1, a strong correlation between
mutational frequency and evolutionary conservation was observed. These findings
parallel prior work demonstrating high mutational frequency in conserved residues
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FIG 7 Insoluble clusters formed by KEAP1 ANCHOR mutants are phase-separated biomolecular condensates. (A) Correlative
epifluorescence and transmission electron microscopy (TEM) images of H1299 cells cotransfected with Keap1-mCh R320Q (red)
and FLAG-NRF2 (not shown). Phase-separated biomolecular condensates are indicated by arrows or are boxed. N, nucleus. (B)
TEM images as described for panel A from two different cells demonstrating cocompartmentalization of biomolecular
condensates with autophagic vesicles (AV). M, mitochondria.
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FIG 8 KEAP1- and NRF2-positive clusters are positive for endogenous p62 and require p62 to form. (A) H1299 cells were
cotransfected with Keap1-mCh WT, R320Q, or R470C (red) and EGFP-Nrf2 (green). Nuclei were stained with DAPI (blue).
Scale bar  10 m; confocal images are shown. (B) H1299 cells were cotransfected with Keap1-mCh R320Q (red) and
FLAG-NRF2 (green or cyan) and stained for endogenous p62 and p62 pS351. Nuclei were stained with DAPI (blue). Scale
bar  10 m; confocal images are shown. (C) H1299 cells were transfected with either control or p62 siRNA, followed by
cotransfection of Keap1-mCh R320Q (red) and FLAG-NRF2 (cyan). Transfected cells were stained for endogenous p62
(green). Scale bar  20 m; confocal images are shown. Nuclei were stained with DAPI (blue). (D) Cartoon schematic of
p62-dependent clusters containing KEAP1, NRF2, p62, and polyUb.
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within TP53 (52). More specifically, the ANCHOR residues and known KEAP1-
inactivating mutations, such as G333 and G480, are within the top 20 most conserved
residues in KEAP1 (40, 44, 45, 116). We suggest that this approach can be used to
prioritize mutations in other tumor suppressors and oncogenes for further study.
The unbiased BioID/MS approach and targeted interrogation of key protein-protein
interactions suggest that with the exception of NRF2, the protein-protein interaction
networks for ANCHOR mutants and wild-type KEAP1 are indistinguishable. We specu-
late that class I and class II ANCHOR mutants may differ in catalytic rates of NRF2
ubiquitylation or degradation; however, without structural insight into each of the
mutations, this hypothesis remains speculative. We would have predicted that other
DLG- and ETGE-containing substrates would also exhibit increased association with
KEAP1 ANCHOR mutants. In fact, appreciable differences were not detected between
ANCHOR mutants and NRF1, which contains both the DLG and ETGE motifs (66, 117).
Of the substrates examined, only PGAM5 demonstrated stabilization in the presence of
KEAP1 ANCHOR mutants; however, the ANCHOR mutants did not associate more with
PGAM5 compared to WT KEAP1.
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FIG 9 Potential genotype-phenotype correlations of KEAP1 ANCHOR mutants. (A) EC50 values of H1299 cells stably expressing indicated constructs and treated
with bleomycin for 72 h. PrestoBlue measurements were plotted and fitted to determine EC50 values. Each point represents the mean of technical
quadruplicates performed in biological triplicate by two independent researchers. Error bars represent the SEMs. P values were determined using a one-way
analysis of variance (ANOVA) with Tukey’s multiple-comparison test. (B) H1299 cells stably expressing the indicated constructs were treated with 1 M
bleomycin for 72 h. Caspase-Glo 3/7 assay was used to measure levels of apoptosis. Each point represents the mean from a single experiment performed in
technical quadruplicate. Error bars represent the SEMs. P values were determined using a one-way ANOVA with Tukey’s multiple-comparison test. (C) Proposed
model correlating KEAP1 cycling dynamics with NRF2 activity and KEAP1 mutation function. (I) Passenger or silent mutations are estimated to represent 25%
of the mutations identified in LUSC. Functionally silent mutations result in low levels of nuclear NRF2 and maintain high rates of KEAP1 conformational cycling.
(II) KEAP1 hypomorphs are estimated to represent 40 to 50% of LUSC mutations. We hypothesize that the ANCHOR mutations result in impaired or delayed
cycling and form p62-dependent phase-separated biomolecular condensates that may represent intermediate aggregates between proteasomal and
autophagic degradation. Consequently, KEAP1 hypomorphs exhibit elevated but not maximal levels of NRF2-dependent transcription. (III) Functionally dead
mutations are unable to bind NRF2 and therefore do not cycle; consequently, NRF2 is neither ubiquitylated nor degraded in a KEAP1-dependent manner,
resulting in maximal levels of nuclear NRF2 transcriptional activity and providing protection against DNA-damaging agents.
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To date, the exact mechanism of how ubiquitylated NRF2 is delivered to the
proteasome has not been described; however, we characterized novel KEAP1 interac-
tions with the ubiquitin chaperone VCP and with two proteasomal ubiquitin receptors,
PSMD2 and PSMD4. The KEAP1-VCP interaction merits further examination, as a recent
report details the roles of VCP and ubiquitin cofactors UFD1/NPL4 and UBXN7 in
removing ubiquitylated NRF2 from the KEAP1-CUL3 complex (27). In our studies, VCP
depletion and inhibition had no effect on NRF2 protein levels in the presence of KEAP1
WT or R320Q, suggesting that VCP may not play a critical role in HEK 293T/17 or H1299
cells. The novel interactions between KEAP1 ANCHOR mutants and PSMD2 and PSMD4
indicate that ANCHOR mutants retain the ability to interact with the proteasome, which
raises several possibilities for how the ANCHOR mutants may impair NRF2 degradation.
First, ubiquitin removal and substrate unfolding of NRF2 may require additional ATP-
dependent reactions or chaperone proteins that were not identified by the BioID
approach. Second, the stabilized KEAP1 tertiary structure predicted by our simulation
modeling and supported by the limited proteolysis and E493D mutation may preclude
the removal of ubiquitin from NRF2 or the dissociation of the E3 complex after the
ANCHOR attempts to present ubiquitylated NRF2 to the proteasome for degradation.
Decreased flexibility at NRF2 contact points is a plausible explanation for the observed
ANCHOR phenotype. It is possible that the R470C mutation disrupts salt bridge
formation with amino acid residues D422 and/or E493, resulting in the observed
stabilization. This mechanism of action is particularly attractive, as the KEAP1 D422N
mutation also results in an ANCHOR phenotype (40). We provide data demonstrating
that mutations to KEAP1 E493 result in an ANCHOR phenotype, as demonstrated by
IP/W.blot and NRF2 transcriptional activity. These data provide further validation of the
DMD simulation studies; additional DMD simulation studies may reveal biologically
relevant mutations. Alterations to KEAP1 architecture and NRF2 contact residues sup-
port the hypothesis that ANCHOR mutants modify KEAP1 structure, resulting in im-
paired KEAP1 conformational cycling.
The identification of p62-dependent clusters was an unexpected phenotype ob-
served with the ANCHOR mutants. These clusters are not specific to ANCHOR mutants,
as they were also observed with KEAP1 WT in H1299 cells; however, ANCHOR mutations
increased the accumulation of these clusters regardless of the cell type studied.
Furthermore, NRF2 was detected in the biomolecular condensates only in the presence
of KEAP1 ANCHOR mutants. The spherical shape of the clusters coupled with their live
cell dynamics of fusion and dissipation along with the TEM imaging indicates mem-
braneless phase separated organelles that have the capacity to cocompartmentalize
with autophagic vesicles (109, 110, 118, 119). Identification of the stoichiometric ratios
of these proteins within the cluster would help to determine the presence and
composition of multimeric KEAP1-NRF2-p62 complexes. Biochemical isolation of the
phase-separated clusters would also be informative for the identification of additional
proteins as well as posttranslational modifications of proteins within the clusters. The
exact nature of these clusters is intriguing given the unique shape and ordering of
proteins within the clusters. Confocal imaging established that the clusters are circular
and contain KEAP1 in the center, surrounded by rings of p62, p62 pS351, polyUb, and,
in some instances, NRF2.
Given the dependence on p62 for cluster formation and the proximity to autophagic
vesicles in TEM imaging, it is possible that these biomolecular condensates represent an
intermediate between proteasomal and autophagic degradation pathways (106, 120–
122). In fact, dynamic cross talk between proteasomal and autophagic degradation
pathways is critical for cellular homeostasis, and proteotoxic stress has been shown to
lead to increased autophagic flux (106, 120, 121). A recent report found that KEAP1/
CUL3 ubiquitylates p62 on its ubiquitin-associated domain (UBA) and that this inter-
action is crucial for the recruitment of p62 into the autophagosome (123, 124).
Furthermore, a role for p62 and polyubiquitin in the formation of phase-separated
autophagic intermediates has been recently defined (125–127). Conformationally
strained KEAP1 due to ANCHOR mutations may result in decreased or absent p62
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ubiquitylation, preventing tethering to LC3 for autophagosome formation and matu-
ration. We note that overexpression of LC3 is sufficient to target KEAP1-NRF2 clusters
to autophagy; however, in the absence of LC3 overexpression, we found no evidence
of autophagic engagement for KEAP1-NRF2 cluster clearance.
KEAP1 ANCHOR mutations are known to increase NRF2 transcriptional activity,
which has been shown to be protective against chemotherapeutic insults (22, 31–33,
36, 112–114). Surprisingly, of the three cytotoxic drugs tested, KEAP1 ANCHOR muta-
tions conferred protection only against bleomycin treatment, which induces DNA
damage in cells through upregulating oxidative stress. This result was initially perplex-
ing given the extensive body of literature demonstrating cytoprotective effects from
elevated NRF2 transcriptional activity (22, 31–33, 36, 112–114); however, this finding
raises several interesting points for discussion. First, mutations in KEAP1 result in a
spectrum of phenotypes: functionally silent/WT, hypomorphic, and functionally dead
(40). Approximately 25% of the KEAP1 LUSC mutations identified from the TCGA studies
behaved comparably to KEAP1 WT (40). These silent mutations result in high levels of
KEAP1 conformational cycling and low levels of nuclear NRF2 and NRF2 transcriptional
activity (Fig. 9C, panel I). Hypomorphic mutations constitute 50% of KEAP1 LUSC
mutations and include the ANCHOR mutations. These hypomorphic mutations result in
impaired NRF2 degradation and may therefore impair KEAP1 cycling. Therefore, these
mutations result in moderate levels of nuclear NRF2 and NRF2 transcriptional activity
(Fig. 9C, panel II). Functionally dead mutations represent 25% of LUSC KEAP1 mutations.
These KEAP1 mutants are unable to bind NRF2 and do not cycle; consequently, they
exhibit elevated levels of both cytosolic and nuclear NRF2, with maximal NRF2 tran-
scriptional activity (Fig. 9C, panel III). Second, genes that are transcriptionally upregu-
lated in the presence of ANCHOR mutants may not be the same target genes as those
upregulated in the presence of functionally dead mutations. Identification of these
differentially expressed genes may provide further mechanistic understanding of ANCHOR
mutations as well as reveal novel targets for clinical intervention.
In summary, through careful biochemical examination, we have defined novel
interactions for KEAP1 with VCP, PSMD2, and PSMD4. Furthermore, we determined that
KEAP1 ANCHOR mutations exclusively impact NRF2 association, appear to stabilize
KEAP1 tertiary structure, and form p62-dependent phase-separated spherical clusters
containing a KEAP1-positive core surrounded by unmodified and phosphorylated p62,
polyUb, and NRF2. These studies reveal molecular insights into KEAP1 regulation and
subcellular localization and suggest unique relationships between KEAP1 mutation,
KEAP1 conformational cycling, and NRF2-driven transcription.
MATERIALS AND METHODS
Tissue culture and transfections. HEK 293T/17 and NCI-H1299 (H1299) cells were obtained from the
American Type Culture Collection (ATCC; Manassas, VA) and authenticated by the ATCC using short
tandem repeat (STR) profiling. Cell lines were passaged for less than 3 months after resuscitation.
Keap1/ mouse embryonic fibroblasts (MEFs) were derived in collaboration with Luke Chen at North
Carolina Central University and immortalized using simian virus 40 (SV40) large T antigen. HEK 293T/17
cells were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine
serum (FBS). Keap1/ MEFs were cultured in DMEM–F-12 supplemented with 10% FBS, 1% nonessential
amino acids, and 1% sodium pyruvate. H1299 cells were grown in RPMI 1640 supplemented with 10%
FBS. All cells were grown in a 37°C humidified incubator with 5% CO2. Expression constructs were
transfected into HEK 293T/17 cells (7.50  106/well in a 6-well format) with Lipofectamine 2000 (52887;
Invitrogen, Carlsbad, CA) according to the manufacturer’s protocols. H1299 cells (3.0  106/well in a
6-well format) and Keap1/ MEFs (1.5  106/well in a 6-well format) were transfected with FuGENE HD
(E231A; Promega, Madison, WI) in accordance with the manufacturer’s protocols. Transfection of siRNAs
in HEK 293T/17 cells (2.0  106 in a 6-well format) was performed with Lipofectamine RNAiMAX
(Invitrogen; 56532) for 72 h unless otherwise stated.
siRNA sequences. Control (CNT) siRNA sequences are as follows: (i) 5= CGU ACG CGG AAU ACU UCG
ACU UCG A 3= and (ii) 5= UCG AAG UAU UCC GCG UAC GCU AAG U 3=. siRNA sequences for NFE2L2 are
as follows: (i) 5= CCG GGA CAG AGT CAC CAT TTG ATT T 3=, (ii) 5= CCC AGC AAT TCT ACC AGC CTC AAC
T 3=, and (iii) 5= GCT ATG TTG GAT GAG ATC AGC CTT A 3=. The siRNA sequences for PGAM5 are as follows:
(i) 5= ACG CGC GCC AUA GAG ACC ACC GAU A 3= and (ii) 5= CAC CUG CCA GGC GUC UGC AAA GUC A
3=. siRNA sequences for p62/SQSTM1 are as follows: (i) 5= CAG AUG GAG UCG GAU AAC U 3=, (ii) 5= CAG
UCU CUG GCG GAG CAG A 3=, and (iii) 5= GGC AGA AUC AGC UUC UGG U 3=. siRNA sequences for VCP
are as follows: (i) 5= GGU AGA AGA GGA UGA UCC A 3=, (ii) 5= CAG UUA CUA UGG AUG ACU U 3=, and
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(iii) 5= GGU AGA UAU UGG AAU UCC U 3=. siRNA sequences for ATG5 are as follows: (i) 5= CAA CUU GUU
UCA CGC UAU A [dT] [dT] 3= and (ii) 5= GAA CCA UAC UAU UUG CUU U [dT] [dT] 3=.
Plasmids, expression vectors, and site-directed mutagenesis. For all FLAG IP experiments,
pcDNA3.1 containing FLAG-GFP was used as a negative control. pcDNA3.1 FLAG-KEAP1 WT, R320Q, and
R470C as well as V51 pIRESpuro-GLUE (pGLUE) KEAP1 WT, R320Q, and R470C constructs were described
previously (40). Entry clones for KEAP1 R320Q and R470C were generated using pcDNA 3.1 FLAG-KEAP1
R320Q and R470C constructs as described previously (40). Phusion high-fidelity DNA polymerase (M0530;
New England BioLabs [NEB], Ipswich, MA) was used to generate the PCR product for the TOPO cloning
reaction using the pCR8/GW/TOPO TA Cloning kit (200517; Thermo Fisher Scientific, Waltham, MA). TOPO
cloning was performed according to the manufacturer’s instructions. Cloning primers were as follows:
forward, 5= ATG CAG CCA GAT CCC AGG 3=, and reverse, 5= TCA ACA GGT ACA GTT CTG CTG GTC 3=.
Resulting entry vectors were then gateway cloned into a custom gateway lentiviral vector, pHAGE-CMV-
FLAG-BirA-DEST, to generate expression constructs for BirA*-KEAP1 R320Q and R470C. Clones were
sequence verified before use. pmCherry-N1 Keap1 WT (mKeap1-mCh WT) and pEGFP-C1-Nrf2 (mEGFP-
Nrf2) were a kind gift from Albena Dinkova-Kostova (University of Dundee, Dundee, United Kingdom)
(15). mKeap1-mCh R320Q, mKeap1-mCh R470C, and pcDNA3.1 FLAG-KEAP1 E493D mutants were
generated from PCR-based mutagenesis using the QuikChange XL site-directed mutagenesis kit (200517;
Agilent, Santa Clara, CA) according to the manufacturer’s instructions. Constructs were sequence verified
before use; primer sequences for the mutagenesis are as follows: R320Q_Forward, 5= CCA CTT TGG GCG
CCT GGC AGG GCA CTG C 3=; R320Q_Reverse, 5= GCA GTG CCC TGC CAG GCG CCC AAA GTG G 3=;
R470C_Forward, 5= CTG CAT ACA GCA AGC AGT TGA GCA CTG CCA C 3=; R470C_Reverse, 5= GTG GCA GTG
CTC AAC TGC TTG CTG TAT GCA G 3=; E493D_Forward, 5= CAC TCG TTC CTG TCT GGG TAG TAA CAC TCA
GC 3=; and E493D_Reverse, 5= GCT GAG TGT TAC TAC CCA GAC AGG AAC GAG TG 3=.
Live-cell imaging. HEK 293T/17 cells were cotransfected with mEGFP-Nrf2 and mKeap1-mCh R320
and imaged the following day. Time-lapse phase-contrast and fluorescence images were acquired every
5 min for 10 h with an Olympus IX70 inverted fluorescence microscope enclosed within an environmental
chamber controlled for temperature, relative humidity, and CO2 and equipped with a 40/0.6 Ph2
LCPlanFl objective lens and a Hamamatsu ORCA C4742-95 charge-coupled-device camera. Data acqui-
sition was carried out with Volocity (version 5.5.1; PerkinElmer), and image processing was performed
with ImageJ and Adobe Photoshop CS software.
IncuCyte live-cell imaging experiments were performed as reported previously, with minor modifi-
cations (128). HEK 293T/17 cells (1.50  106/well in a 24-well format) were plated and transfected the
next day with FLAG-KEAP1 WT, R320Q, or R470C (150 ng/well) along with mEGFP-Nrf2 or Venus-NRF2
(100 ng/well). Plates were immediately transferred into the IncuCyte ZOOM (Essen BioScience, Ann Arbor,
MI) and housed inside a cell incubator at 37°C with 5% CO2. Images were taken every hour for 24 h with
a 20 objective from four fields per well and from four technical replicates per condition in the phase
and green channels (400-ms acquisition). Automated image processing on the fluorescence and phase
channels was accomplished by applying an appropriate processing definition. Total green object
integrated intensity (GCU  m2/image) was normalized by cell confluence. Data presented represent
the averages from three biological replicates and are reported as means  standard errors of the means.
Immunopurification and Western blotting. For FLAG/mCherry immunopurification, HEK 293T/17
cells (7.5  106/well in a 6-well format) or H1299 cells (3.0  106/well in a 6-well format) were seeded
and transfected and/or treated the following day for up to 24 h. Cells were washed with Dulbecco’s
phosphate-buffered saline (DPBS) and lysed in 255 l (per well) of 0.1% NP-40 lysis buffer (0.1% NP-40,
10% glycerol, 50 mM HEPES [pH 8.0], 150 mM NaCl, and 2 mM EDTA) supplemented with Halt protease
inhibitor Cocktail 100 (Thermo Scientific; 78429), Halt phosphatase inhibitor cocktail (100; Thermo
Scientific; 78426), and 10 mM N-ethylmaleimide (NEM) (Thermo Scientific; 23030). Cells were lysed on ice
for 30 min, followed by a 30-min centrifugation at 16,000  g at 4°C. Cleared lysates were quantified
using the Pierce bicinchoninic acid (BCA) protein assay kit (Thermo Scientific; 23225) and incubated with
an EZview red anti-FLAG M2 affinity gel (Sigma F2426; St. Louis, MO) or 1 g of mCherry antibody
(ab16745; Abcam, Cambridge, UK) prior to being washed 4 times with 0.1% NP-40 lysis buffer and eluted
with 4 NuPAGE LDS sample buffer (NP0007; Life Technologies, Carlsbad, CA). For immunoprecipitation
of mKeap1-mCh or mEGFP-Nrf2, cells were lysed and cleared as described above and precleared for 1 h
with Pierce protein A/G-agarose (Thermo Scientific; 20421). Lysates were then incubated with mCherry
antibody or GFP antibody (Abcam; ab290) overnight at 4°C. The following day, lysates were incubated for
1 h with Pierce protein A/G resin, followed by elution with NuPAGE LDS sample buffer as described
above. For siRNA experiments, HEK 293T/17 cells were lysed in radioimmunoprecipitation assay (RIPA)
buffer (1% NP-40, 0.1% SDS, 10% glycerol, 25 mM Tris-HCl [pH 7 to 8], 0.25% sodium deoxycholate, 150
mM NaCl, and 2 mM EDTA) supplemented with protease and phosphatase inhibitor cocktails and 10 mM
NEM 72 h posttransfection.
Antibodies used for W.blot analysis. GFP (ab290), HMOX1 (ab13243), mCherry (ab16745), and
PGAM5 (ab126534) antibodies were purchased from Abcam (Cambridge, UK). MCM3 (A300-192A), PALB2
(A301-246A), PSMD4 (A303-55A), p62/SQSTM1 A302-856A), and vesicular stomatitis virus glycoprotein
(VSV-G) (A190-131A) antibodies were purchased from Bethyl Laboratories (Montgomery, TX). ATG5
(2630), BCL2 (2876B), CUL3 (2759), IKBKB (2684), K48 linkage-specific polyubiquitin clone D9D5 (8081),
LC3A/B clone D3U4C XP (12741), NBR1 clone D2E6 (9891), NRF1 (8052), p62/SQSTM1 (8025), VCP (2648),
and VPS34 (4263) were purchased from Cell Signaling Technologies (Danvers, MA). PSMD2 (PA5-27663)
antibody was obtained from Invitrogen. The phosphorylated p62 (SQSTM1) (Ser351) p62/SQSTM1
(PM074) antibody was obtained from MBL International (Woburn, MA). KEAP1 (10503-2-AP) antibody was
obtained from Proteintech (Rosemont, IL). Antihemagglutinin (anti-HA) high-affinity rat antibody (11 867
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423 001) was purchased from Roche Diagnostics (Mannheim, Germany). NRF2-H300 (SC-13032) antibody
was purchased from Santa Cruz Biotechnology (Dallas, TX). Actin (A5316), FLAG M2 (F1804), and beta
tubulin (T7816) antibodies were purchased from Sigma. The following secondary antibodies were
purchased from Jackson ImmunoResearch (West Grove, PA): peroxidase-conjugated IgG fraction mono-
clonal mouse anti-rabbit IgG, light chain specific (211-032-171), peroxidase-conjugated AffiniPure goat
anti-mouse IgG, light chain specific (115-035-174), peroxidase-conjugated AffiniPure donkey anti-mouse IgG
(HL) (715-035-150), peroxidase-conjugated AffiniPure donkey anti-goat IgG (HL) (705-035-003),
peroxidase-conjugated AffiniPure donkey anti-rat IgG (HL) (712-035-150), and peroxidase-conjugated
AffiniPure donkey anti-rabbit IgG (HL) (711-035-152). Secondary antibodies for LI-COR were purchased
from LI-COR Biosciences (Lincoln, NE): IRDye 680LT goat anti-rabbit IgG (925-68021), IRDye 680LT goat
anti-mouse IgG (925-68020), IRDye 800CW goat anti-mouse IgG (925-32210), and IRDye 800CW goat
anti-rabbit IgG (925-32211).
Antibodies used for IF analysis. LAMP2 antibody (555803) was obtained from BD Biosciences
(Franklin, NJ). The LC3B (2775) and LC3B D11 XP (3868) antibodies were obtained from Cell Signaling
Technology. The polyubiquitinylated conjugate clone FK1 antibody (BML-PW8805) and the proteasome
20S  subunit antibody (BML-PW8265-0100; 1:150) were purchased from Enzo Life Sciences (Farm-
ingdale, NY). PSMD2 antibody (PA5-27663; 1:200) was obtained from Invitrogen. PSMD4 antibody
(A303-855A; 1:200) was obtained from Bethyl Laboratories. The following secondary antibodies were all
purchased from Jackson ImmunoResearch Laboratories: fluorescein isothiocyanate (FITC)–AffiniPure
donkey anti-mouse IgG (715-095-150), Alexa Fluor 647–AffiniPure donkey anti-rabbit IgG (711-605-152),
Alexa Fluor 647–AffiniPure donkey anti-mouse IgG (715-505-150), and rhodamine red-X (RRX)–AffiniPure
donkey anti-mouse IgG (715-295-150).
Small-molecule reagents. The following chemicals were purchased from Cayman Chemicals (Ann
Arbor, MI): bleomycin sulfate (13877), cisplatin (13119), CB-5083 (19311), N2,N4-dibenzylquinazoline-2,4-
diamine (DBeQ; 15318), and Eeyrestatin 1 (Eey1; 10012609). Cycloheximide (CHX; 1010083) was pur-
chased from MP Biomedicals (Santa Ana, CA). The following chemicals were purchased from Sigma:
chloroquine (CQ; C6628), L-sulforaphane (SFN; S6317), and tert-butylhydroquinone (tBHQ; 112941).
Bardoxolone methyl (CDDO; S8078) was obtained from Selleck Chemicals (Houston, TX). Paclitaxel
(TXD01) was obtained from Cytoskeleton, Inc. (Denver, CO). The following chemicals were purchased
from Calbiochem (Darmstadt, Germany): MG-132 (474790) and MLN4924 (505477001).
Immunostaining and confocal images. Immunostaining and confocal imaging were performed as
reported previously, with minor modifications (128). Briefly, HEK 293T/17 or H1299 cells were plated on
coverslips coated with 10 g/ml of fibronectin in the appropriate culture media and allowed to attach
overnight. For experiments that required exogenous expression of tagged proteins, transfection was
performed 24 h postplating, and cells were stained the following day. Cells were fixed in 4% parafor-
maldehyde in cytoskeletal buffer [5 mM piperazine-N,N=-bis(2-ethanesulfonic acid) (PIPES; pH 6.0), 137
mM NaCl, 5 mM KCl, 1.1 mM Na2HPO4, 0.4 mM KH2PO4, 0.4 mM MgCl2, 0.4 mM NaHCO3, 2 mM EGTA, and
50 mM glucose] for 15 min and permeabilized with 0.1% Triton X-100 in phosphate-buffered saline (PBS)
for 5 min. After blocking with 1% bovine serum albumin (BSA) in PBS, cells were incubated overnight
with the primary antibodies and then incubated with the appropriate fluorescence-conjugated second-
ary antibodies for 1 h. The following primary antibodies were used: anti-FLAG (1:1,000; Sigma), anti-p62
(1:150; Cell Signaling Technology), anti-p-S351-p62 (1:300; MBL International), anti-LC3B (1:150; Cell
Signaling Technology), anti-LAMP2 (1:150; BD Biosciences), and anti-polyubiquitinylated conjugate FK1
(1:250; Enzo Life Sciences). The following secondary antibodies were used: FITC–anti-mouse IgG (1:300),
Alexa Fluor 647–anti-rabbit IgG (1:500), Alexa Fluor 647–anti-mouse IgG (1:300), and RRX–anti-mouse IgG
(1:2,000). 4=,6-Diamidino-2-phenylindole (DAPI) staining was performed for nuclear detection. Coverslips
were mounted to slides using the ProLong gold antifade mountant with DAPI (P36935; Thermo Fisher
Scientific), and images were acquired using a Zeiss LSM 710 confocal laser-scanning microscope
equipped with 40/1.3-numerical aperture (NA) Oil Plan Neo and 63/1.4-NA Oil Plan Apo objective
lenses.
Proximity ligation assays. For detection of KEAP1 and NRF2 interactions, proximity ligation was
performed with a Duolink II proximity ligation assay kit according to the protocol provided by the
manufacturer (Sigma; DUO092101). Briefly, HEK 293T/17 cells stably expressing FLAG-KEAP1 (WT or
mutants) were plated on fibronectin-coated coverslips, allowed to attach, fixed, and permeabilized as
described above. For the PLA experiments with H1299 cells, transfections with the desired plasmids were
performed 1 day after plating cells on coverslips. Cells were then incubated in blocking solution in a
humidified chamber at 37°C for 30 min, followed by overnight coincubation with rabbit polyclonal
antibodies against NRF2 (Santa Cruz; 1:200) and mouse monoclonal antibody against FLAG (Sigma;
1:1,000) in antibody diluent solution at 4°C. Cells were washed in buffer A and incubated with PLA probes
(Sigma Duolink In Situ PLA Probe Anti-Rabbit PLUS [DUO92002] and Duolink In Situ PLA Probe
Anti-Mouse MINUS [DUO92004] in antibody diluent (1:5 dilution) for 1 h at 37°C. They were then washed
in buffer A and incubated with ligation solution (1:5 dilution of ligation buffer and 1:40 dilution of ligase
in pure water) for 30 min at 37°C. After ligation, cells were washed in buffer A and subjected to
amplification with detection reagents red (1:5 dilution of amplification stock and 1:80 dilution of
polymerase in water) for 100 min at 37°C. Amplified samples were washed in buffer B, washed in buffer
A, and counterstained for microtubules using antitubulin-FITC antibodies (Sigma; 1:500 dilution). The
coverslips were mounted with Duolink II mounting medium with DAPI for nuclear detection. When
analyzing PLA preparations in HEK 293T/17 cells, confocal Z-stack images of 10-m thickness were taken
with a Z-step of 0.5 m (about 21 slices) at 512 by 512 pixels, using a Zeiss LSM710 spectral confocal
laser-scanning microscope equipped with a40/1.4 Oil Dic M27PlanApo objective lens. ImageJ software
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was used to project all 21 slices per field into a two-dimensional (2D) image. When analyzing PLA
preparations in H1299 cells, a single optical slice was captured per field from a depth of 4 to 5 m above
the substrate to ensure that sampling was done from the same level for all preparations. Three channel
images were taken for nine random fields per condition. Experiments were done in three biological
replicates. The number of nuclei and PLA dots per image were quantified using BlobFinder software
(129). The ratio of PLA dots to nuclei was set to 1 in FLAG-KEAP1 WT-expressing cells (untreated or
dimethyl sulfoxide [DMSO] treated) and used to calculate PLA dot fold induction in cells expressing
KEAP1 mutants or following treatment with NRF2 inducers.
Correlative fluorescence and transmission electron microscopy. Transfected H1299 cells were
fixed with 4% paraformaldehyde, and an Olympus IX81 inverted light microscope was used to capture
images in phase and red channels in order to map target regions to be examined at the ultrastructural
level. Next, cells were fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, postfixed in 1%
buffered osmium tetroxide, dehydrated with a graded ethanol series, and embedded in Poly/Bed 812
epoxy resin (Polysciences, Inc., Warrington, PA). Ultrathin sections (80 nm) were cut, mounted on copper
grids, and double stained with 4% uranyl acetate and Reynolds’ lead citrate. Sections were observed
using a JEOL JEM-1230 transmission electron microscope (JEOL USA Inc., Peabody, MA) operating at 80
kV. Digital images were taken using a Gatan Orius SC1000 CCD camera and Gatan Microscopy Suite v3.0
software (Gatan, Inc., Pleasanton, CA).
Morphometric analysis of KEAP1-positive clusters. For determination of KEAP1-positive cluster
diameter, multiple images of H1299 cells transiently expressing mKeap1-mCh WT and R320Q were
randomly captured using a confocal microscope as described above (“Immunostaining and confocal
images”). The diameter of the mKeap1-mCh-positive clusters was measured using the red channel scaled
images in the Zeiss ZEN 2011 (blue edition) software (Zeiss, Thornwood, NY).
For determination of the mKeap1-mCh-positive cluster circularity index, multiple images of mKeap1-
mCh WT- and R320Q-expressing cells were randomly captured using an Olympus IX81 inverted light
microscope. Binary images were generated in ImageJ by equally adjusting the threshold levels in red
channel images. Circularity index values were obtained by using the ImageJ Analyze Particles plugin in
which circularity is determined using the formula 4pi(area/perimeter2); a perfect circle is defined as a
circularity index of 1.0.
KEAP1 ubiquitylation experiments. Ubiquitylation of KEAP1 under denaturing conditions was
performed with HEK 293T/17 cells transiently transfected with VSV-Ub1 or Venus-NPM1 and pGLUE-
KEAP1 WT, R320Q, or R470C. Cells were lysed in preboiled SDS denaturing buffer (25 mM Tris, 150 mM
NaCl, 1% SDS, and 1 mM EDTA) and boiled for 10 min. The cells were then diluted 1:5 in 0.5% NP-40
buffer (0.5% NP-40, 25 mM Tris-HCl [pH 7-8], and 150 mM NaCl) and normalized for protein content. A
total of 250 g of protein was reserved for input, and 500 g of the lysate was immunoprecipitated with
FLAG antibody for 2 h at 4°C. FLAG beads were washed 4 with SDS denaturing buffer diluted 1:10 in
0.5% NP-40 lysis buffer. FLAG beads were then eluted with NuPAGE lysis buffer and boiled for 10 min at
70°C.
BioID affinity purification and peptide generation. HEK 293T/17 cells stably expressing BirA*-
KEAP1 WT, R320Q, or R470C were treated with 50 M biotin (Sigma; B4639) for 24 h. Cells were lysed in
RIPA buffer supplemented with protease and phosphatase inhibitors, 10 mM NEM, and 1 l of Benzonase
(Sigma E1404), cleared with ultracentrifugation, and protein normalized. Five milligrams of protein was
used for streptavidin affinity purification (AP). Streptavidin-Sepharose high-performance beads (GE
Healthcare 17-5113-01, Uppsala, Sweden) were washed three times in RIPA buffer prior to AP overnight
at 4°C with nutation. Beads were washed once with RIPA buffer, twice with TAP lysis buffer (10% glycerol,
50 mM HEPES [pH 8.0], 150 mM NaCl, 2 mM EDTA, and 0.1% NP-40), and three times with 50 mM
ammonium bicarbonate (pH 8.0). The precipitated proteins were trypsinized with 1 g of trypsin
(Promega; V5111) for 16 h, followed by another 0.5 g of trypsin for 2 h. Trypsinization was performed
directly on beads using a modified filter-aided sample preparation (FASP) protocol followed by desalting
via a Pierce C18 spin column (Thermo; 89870) and ethyl acetate cleanup.
Mass spectrometry, data filtering, and bioinformatics. Reverse-phase nano-high-performance
liquid chromatography (nano-HPLC) coupled with a nanoACQUITY ultraperformance liquid chromatog-
raphy (UPLC) system (Waters Corporation, Milford, MA) was used to separate trypsinized peptides.
Trapping and separation of peptides were performed in a 2-cm column (Pepmap 100; 3-m particle size
and 100-Å pore size), and a 25-cm EASYspray analytical column (75-m inside diameter [i.d.], 2.0-m C18
particle size, and 100-Å pore size) at 300 nl/min and 35°C, respectively. Analysis of a 180-min gradient of
2 to 25% buffer B (0.1% formic acid in acetonitrile) was performed on an Orbitrap Elite mass spectrometer
(Thermo Scientific). Data acquisition and ion source settings were previously published (65).
All raw mass spectrometry data were searched using MaxQuant version 1.5.2.6 (130, 131). Search
parameters were as follows: UniProtKB/Swiss-Prot human canonical sequence database (downloaded 23
July 2013), static carbamidomethyl cysteine modification, specific trypsin digestion with up to two
missed cleavages, variable protein N-terminal acetylation and methionine oxidation, match between
runs, and label-free quantification (LFQ) with a minimum ratio count of 2 (132). Searched files were
analyzed using Perseus version 1.5.1.6 for data filtering and visualization (133). Protein identifications
were filtered to a 1% false-discovery rate (FDR), and potential contaminants and decoys were removed.
LFQ intensities were log2 transformed and filtered on proteins present in three replicates of at least one
group. Missing values were imputed from a normal distribution using a downshift of 1.8 and a
distribution width of 0.4. For volcano plots illustrating BioID/MS data, P values were determined using a
two-tailed t test, and the FDR was calculated using the permutation test implemented in Perseus. The
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mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the
PRIDE partner repository with the data set identifier PXD008411 (134).
Sequence variability for NRF2 and KEAP1. The protein BLAST server was used to find 500 unique
sequences for each gene and to analyze the sequence conservation for human NRF2 (UniProt accession
number Q16236) and KEAP1 (UniProt accession number Q14145) (132, 135). All of the identified genes
had at least 45% amino acid identity to the query sequence. The PROMALS3D webserver was used to
create a multisequence alignment; default settings were used (136). Shannon entropy was calculated for
the multiple sequence alignments using the Protein Variability Server with the default settings (50).
DMD simulation data. Five replicate DMD simulations of one million steps each for both KEAP1 WT
and R470C were performed in the presence of the NRF2 peptide (87–90).
Limited proteolysis. Keap1/ MEFs were seeded in 6-well plates and allowed to adhere overnight.
The following day, cells were transfected with FLAG-KEAP1 constructs using FuGene HD according to the
manufacturer’s protocol. Twenty-four hours posttransfection, cells were washed twice with PBS and
harvested in PBSt (0.1% Triton X-100 in PBS). Cells were snap-frozen in liquid nitrogen, thawed, and lysed
for 1 h at 4°C. Lysates were cleared at 16,000  g for 10 min at 4°C and protein normalized. Lysates were
diluted to 1 mg/ml, and 75-l aliquots were taken. Twenty-five-microliter volumes of trypsin (Sigma;
T1426) at the desired concentrations were added to lysates, and limited proteolysis was allowed to
proceed for 15 min on ice. Reactions were quenched with 100 l of complete protease inhibitor and 100
M phenylmethylsulfonyl fluoride (PMSF). Samples were diluted with 4 LDS sample buffer and
dithiothreitol (DTT) prior to boiling at 70°C for 10 min.
hQR41-ARE luciferase assays. The pGL2-hQR41-ARE luciferase assay construct was a kind gift from
Jeffrey Johnson (92). The pRL-TK Renilla luciferase construct served as a control for transfection efficiency
and cell viability (Promega; E2241). HEK 239T/17 cells were seeded in a 48-well format and cultured until
70% confluent. Cells were transfected with pGL2-hQR41-ARE luciferase (40 ng), pRL-TK (10 ng), cGLUE-
NRF2 (10 ng), and FLAG-KEAP1 WT, R320Q, R470C, or E493D (100 ng) using Lipofectamine 2000 in
accordance with the manufacturer’s instructions. Twenty-four hours posttransfection, cells were lysed in
50 l of 1 passive lysis buffer (PLB) (Promega; E1941) for 15 min at room temperature. Firefly luciferase
and Renilla luciferase were quantified using a dual-luciferase reporter assay system (Promega; E1960).
Briefly, 10 l of cell lysate was transferred to a 96-well plate (PerkinElmer; 6005030) to which 10 l of
luciferase assay reagent II (LAR II) was added, followed by luciferase measurement on a PerkinElmer
EnSpire plate reader (PerkinElmer, Waltham, MA). Next, to quench the reaction and quantify Renilla
luciferase, 10 l of Stop and Glo reagent was added and Renilla luciferase activity was measured. For all
experiments, the ratio of hQR41-ARE firefly luciferase (FF) to Renilla luciferase for each well was
determined. All experiments were performed with six technical replicates across five biological experi-
ments conducted by two independent researchers. Resulting data were plotted and analyzed using
Microsoft Excel.
Triton X-100 solubility assays. Harvested cell pellets were lysed for 1 h at 4°C in 1% Triton X-100
lysis buffer (1% Triton X-100, 10% glycerol, 25 mM Tris-HCl [pH 7 to 8], 150 mM NaCl, 2 mM EDTA)
containing 10 l of RQ1 DNase (Promega; M6101). Forty-five microliters of lysate was removed for “total”
sample, and the remaining lysate was subjected to centrifugation at 20,000  g for 15 min at 4°C.
Supernatant was removed, and 45 l was reserved for the soluble fraction, to which was added 20 l of
4 LDS sample buffer with 10 mM DTT. The insoluble fraction was dissolved in 200 l of 1 SDS sample
buffer with DTT. Samples were sonicated with two 10-s pulses at 10% intensity using a Branson
Ultrasonics sonifier (Branson S-450; Thermo Scientific) prior to SDS-PAGE.
Cell viability assays. H1299 cells (3.5  103/well in a 96-well format) were seeded and allowed to
adhere overnight. Serial drug dilutions were prepared, and cells were treated for 72 h. PrestoBlue cell
viability reagent (Life Technologies Corporation; A13262) was added to wells according to the manu-
facturer’s protocol. Measurements of resazurin conversion as a surrogate for mitochondrial respiration
were taken by fluorescence on a PerkinElmer Enspire plate reader (PerkinElmer). All experiments were
performed in technical quadruplicate and biological triplicate by two independent researchers. Resulting
data were plotted and analyzed using GraphPad Prism software version 7.0.
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